Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 1
2016 2
2019 2
2020 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Daily intranasal palivizumab to prevent respiratory syncytial virus infection in healthy preterm infants: a phase 1/2b randomized placebo-controlled trial.
Mazur NI, Löwensteyn YN, Terstappen J, Leusen J, Schobben F, Cianci D, van de Ven PM, Nierkens S, Bont LJ; Narsyn Study Group. Mazur NI, et al. EClinicalMedicine. 2023 Nov 25;66:102324. doi: 10.1016/j.eclinm.2023.102324. eCollection 2023 Dec. EClinicalMedicine. 2023. PMID: 38192587 Free PMC article.
Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Nitz U, Gluz O, Christgen M, Kates RE, Clemens M, Malter W, Nuding B, Aktas B, Kuemmel S, Reimer T, Stefek A, Lorenz-Salehi F, Krabisch P, Just M, Augustin D, Liedtke C, Chao C, Shak S, Wuerstlein R, Kreipe HH, Harbeck N. Nitz U, et al. Breast Cancer Res Treat. 2019 May;175(1):265-266. doi: 10.1007/s10549-018-05105-8. Breast Cancer Res Treat. 2019. PMID: 30632020 Free PMC article.
The article Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial, written by Ulrike Nitz, Oleg Gluz, Matthias Christgen, …
The article Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data …
Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
Kolberg-Liedtke C, Gluz O, Heinisch F, Feuerhake F, Kreipe H, Clemens M, Nuding B, Malter W, Reimer T, Wuerstlein R, Graeser M, Shak S, Nitz U, Kates R, Christgen M, Harbeck N. Kolberg-Liedtke C, et al. Breast Cancer Res. 2020 May 14;22(1):47. doi: 10.1186/s13058-020-01283-w. Breast Cancer Res. 2020. PMID: 32408905 Free PMC article.
West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.
Gluz O, Nitz UA, Christgen M, Kates RE, Shak S, Clemens M, Kraemer S, Aktas B, Kuemmel S, Reimer T, Kusche M, Heyl V, Lorenz-Salehi F, Just M, Hofmann D, Degenhardt T, Liedtke C, Svedman C, Wuerstlein R, Kreipe HH, Harbeck N. Gluz O, et al. J Clin Oncol. 2016 Jul 10;34(20):2341-9. doi: 10.1200/JCO.2015.63.5383. Epub 2016 Feb 29. J Clin Oncol. 2016. PMID: 26926676 Clinical Trial.
The Eighth Liquid Matter Conference.
Dellago C, Kahl G, Likos CN. Dellago C, et al. J Phys Condens Matter. 2012 Jul 18;24(28):280301. doi: 10.1088/0953-8984/24/28/280301. Epub 2012 Jun 27. J Phys Condens Matter. 2012. PMID: 22740596
The Eighth Liquid Matter Conference contents The Eighth Liquid Matter ConferenceChristoph Dellago, Gerhard Kahl and Christos N Likos Comparing light-induced colloidal quasicrystals with different rotational symmetriesMichael Schmiedeberg and Holger Stark Hydrogen bond network rel …
The Eighth Liquid Matter Conference contents The Eighth Liquid Matter ConferenceChristoph Dellago, Gerhard Kahl and Christos N Likos Compari …